血清基质金属蛋白酶-2：一种用于癫痫诊断的潜在生物标志物。

Serum matrix metalloproteinase-2: A potential biomarker for diagnosis of epilepsy.

作者信息

Wang Rui, Zeng Guang Qun, Tong Rui Zhan, Zhou Dong, Hong Zhen

机构信息

Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Department of Laboratory, Pengzhou People's Hospital, Chengdu, Sichuan, People's Republic of China.

出版信息

Epilepsy Res. 2016 May;122:114-9. doi: 10.1016/j.eplepsyres.2016.02.009. Epub 2016 Feb 27.

DOI:10.1016/j.eplepsyres.2016.02.009

PMID:27016865

Abstract

OBJECTIVES

In this study, we evaluate the utility of serum metalloproteinase-2 (MMP-2) as a biomarker for the diagnosis of epilepsy.

METHODS

We assessed serum MMP-2 levels in 233 epileptic and 97 healthy control subjects. Control subjects had no complaints or signs of neurological disorders for at least 12 months prior to serum collection. Serum MMP-2 levels were determined using the Luminex technology.

RESULTS

Compared with controls, subjects with epilepsy had significantly lower serum MMP-2 concentrations (P<0.05). There was no significant difference between males and females in either group (P>0.05). Serum MMP-2 concentrations were highly correlated with age in both groups, and this correlation was strongest for males. When an MMP-2 cut-off value of 175.40ng/ml was used, the sensitivity for distinguishing subjects with epilepsy from controls was 71.13% and the specificity was 62.66%.

CONCLUSIONS

Our results reveal that serum MMP-2 may be a potential biomarker for the diagnosis of epilepsy.

摘要

目的

在本研究中，我们评估血清金属蛋白酶-2（MMP-2）作为癫痫诊断生物标志物的效用。

方法

我们评估了233例癫痫患者和97例健康对照者的血清MMP-2水平。对照者在采集血清前至少12个月没有神经疾病的主诉或体征。使用Luminex技术测定血清MMP-2水平。

结果

与对照组相比，癫痫患者的血清MMP-2浓度显著降低（P<0.05）。两组中男性和女性之间均无显著差异（P>0.05）。两组中血清MMP-2浓度均与年龄高度相关，且这种相关性在男性中最强。当使用MMP-2临界值175.40ng/ml时，区分癫痫患者与对照者的敏感性为71.13%，特异性为62.66%。